bs-13274R [Primary Antibody]
GALNT13/GalNAc-T13 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: GALNT13/GalNAc-T13

Immunogen Range: 351-450/556


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 114805

Source: KLH conjugated synthetic peptide derived from human GALNT13/GalNAc-T13

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

The UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) family of enzymes are substrate-specific proteins that catalyze the transfer of GalNAc (N-acetylgalactosamine) to serine and threonine residues onto various proteins, thereby initiating mucin-type O-linked glycosylation in the Golgi apparatus. GalNAc-T13 (Polypeptide N-acetylgalactosaminyltransferase 13), also known as UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 13, is a 556 amino acid protein that displays much stronger enzymatic activity than GalNAc-1 towards GalNAc transfer to mucin peptides such as Muc5a and Muc7. The N-terminal domain is involved in substrate binding and manganese coordination, while the C-terminal domain is involved in UDP-Gal binding and catalytic reaction. With specific expression in the central nervous system, GalNAc-T13 may be responsible for the synthesis of Tn antigen in neuronal cells, which is a universal carcinoma marker on malignant cells.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
ICC(1:100-500)

Predicted Molecular Weight: 64


Cross Reactive Species: Rat

Predicted Cross Reactive Species: Human
Mouse
Dog
Cow
Sheep
Pig
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Liang Jin-xiao. et al. A novel glycosylation-related gene signature predicts survival in patients with lung adenocarcinoma. BMC BIOINFORMATICS. 2022 Dec;23(1):1-15Read more>>
VALIDATION IMAGES

VSC4.1 Cell lysates probed with GALNT13/GalNAc-T13 Polyclonal Antibody, unconjugated (bs-13274R) at 1:300 overnight at 4°C followed by a conjugated secondary antibody for 60 minutes at 37°C.